SCHEMBL6995895

SCHEMBL6995895

OC(CCl)CN1CCC(Cc2ccccc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.69
PRMT6 Q96LA8 1/20 0.69
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
DRD4 P21917 4/20 0.67
GRIN2D O15399 3/20 0.67
GRIN3B O60391 3/20 0.67
ADRA1D P25100 3/20 0.67
ADRA1A P35348 3/20 0.67
ADRA1B P35368 3/20 0.67
GRIN1 Q05586 3/20 0.67
GRIN2A Q12879 3/20 0.67
GRIN2B Q13224 3/20 0.67
GRIN2C Q14957 3/20 0.67
GRIN3A Q8TCU5 3/20 0.67
CCR3 P51677 1/20 0.62
DRD2 P14416 1/20 0.58
ATM Q13315 1/20 0.57
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7245946 0.87 CARM1 (0.71) CARM1PRMT6MEN1KMT2ADRD4
SCHEMBL6990168 0.86 GRIN1 (0.65) CARM1PRMT6MEN1KMT2ADRD4
SCHEMBL6986594 0.85 CARM1 (0.69) CARM1PRMT6MEN1KMT2ADRD4
SCHEMBL5888785 0.84 CARM1 (0.67) CARM1PRMT6MEN1KMT2ADRD4
Hydrochloric Acid SCHEMBL7035790 0.84 CARM1 (0.67) CARM1PRMT6MEN1KMT2ADRD4
SCHEMBL13229781 0.82 DRD4 (0.74) CARM1PRMT6MEN1KMT2ADRD4
SCHEMBL7269243 0.80 KDM4E (0.66) DRD4CCR3ATMCYP2D6ABCB1
SCHEMBL31549529 0.79 CCR3 (0.77) CARM1PRMT6GRIN2BCCR3ATM
SCHEMBL9159777 0.79 SLC18A3 (0.73) MEN1KMT2ADRD2
SCHEMBL6996540 0.79 CARM1 (0.64) CARM1PRMT6MEN1KMT2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642256-B2 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders WARNER-LAMBERT COMPANY LLC 2003-11-04 US disclosed
EP-1345935-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS Warner-Lambert Company LLC (US) 2003-09-24 EP disclosed
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists KORNBERG BRIAN EDWARD (US) 2003-01-23 US disclosed
WO-2002050070-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists GRIN1, OPRD1, OPRM1 CARM1 683/4885PRMT6 1074/4885MEN1 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.